1431868-80-2

Upstream product

• 2038-57-5 3-Phenylpropan-1-amine 
• 1431868-67-5 (RS)-methyl 2-(2-chlorophenylsulfonyl)-2-azaspiro[3.3]heptane-5-carboxylate 
• 1263296-85-0 (R,S)-methyl 2-benzhydryl-2-azaspiro[3.3]heptane-5-carboxylate 
• 1431868-78-8 methyl 2-azaspiro[3.3]heptane-5-carboxylate 

Downstream Products

• 1431868-48-2 (R)-2-(2-chlorophenylsulfonyl)-N-(3-phenylpropyl)-2-azaspiro[3.3]heptane-5-carboxamide 
• 1431868-49-3 (S)-2-(2-chlorophenylsulfonyl)-N-(3-phenylpropyl)-2-azaspiro[3.3]heptane-5-carboxamide 

Relevant academic research and scientific papers

AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

Provided are compounds of Formula I, stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein A, L1, L2, R1 and R2 are defined herein, a pharmaceutical composition and methods of using such compounds as soluble epoxide hydrolase inhibitors. R1-L1-A-L2-R2

AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided are compounds of Formula I, [in-line-formulae]R1-L1-A-L2-R2??(I),[/in-line-formulae] and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein A, L1, L2, R1 and R2 are defined herein. The present invention also provides a pharmaceutical composition and methods of using such compounds. The compounds are useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of Soluble Epoxide Hydrolase (sEH).